Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces positive results in its Phase 1b First-in-Human trial, COMPOSER-1, of MB310 in ulcerative colitis (UC) patients. […]
Verb Biotics U.S. Consumer Health Survey of 2,000 adults reported that 73% of consumers experience symptoms related to mental health, including stress and poor sleep. Among these, 40% said their symptoms affect daily functioning, highlighting […]
EnteroBiotix, a clinical-stage biopharmaceutical company focused on developing best-in-class therapies for gut health, today announced positive final results from TrIuMPH, a Phase 2a clinical trial evaluating EBX-102-02, a next-generation oral full-spectrum microbiome therapeutic, in patients […]
AOB Pharma, Inc. (“AOBiome”), a leading clinical-stage biotechnology company focusing on inflammatory skin conditions with their lead asset B244 for the treatment of mild to moderate atopic dermatitis (AD) and pruritus, received a positive decision […]
University of California San Diego researchers have developed an innovative new tool called coralME to better understand how microbes interact with each other and their environment to influence health. The tool rapidly creates detailed genome-scale […]
Researchers at The University of Texas MD Anderson Cancer Center have uncovered unexpected traces of bacteria within brain tumors. This discovery offers new insights into the environment in which brain tumors grow and sets the […]
Delivering live biotherapeutics orally remains one of the challenges in microbiome therapy. In this white paper, Evonik presents a real-world case study of how EUDRACAP® Select—a ready-to-fill enteric capsule—enabled the safe and targeted delivery of […]
Siolta Therapeutics, a clinical-stage biotech company developing first-in-class live biotherapeutic products (LBPs), today announced positive top-line results from the Phase 2 ADORED study (Allergic Disease Onset pREvention stuDy) of STMC-103H, its lead investigational oral microbial […]
Ferring Pharmaceuticals shared an oral presentation last month detailing microbiome restoration from the Phase 3b CDI-SCOPE study among patients with recurrent C. difficile (C. diff) infection (CDI) who received REBYOTA® (fecal microbiota, live – jslm). This research was […]
Ascribe Bio, an innovator in natural crop protection, announced the closing of an oversubscribed $12 million Series A financing round, co-led by Corteva, through its Corteva Catalyst platform, and Acre Venture Partners. The financing also included participation […]
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, announced that CARB-X, a global non-profit partnership accelerating antibacterial products to address drug-resistant bacteria, will provide up to $3.6 million in additional non-dilutive funding to […]